Q2 2025 Earnings Call Transcript August 7, 2025 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

NTLA-2002 has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration, the Innovation Passport by the U.K. Medicines and ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

Intellia Therapeutics, Inc. achieved positive phase 1/2 results using NTLA-2002 for HAE patients: 8 out of 11 patients taking higher doses of 50 mg of NTLA-2002 were attack-free during the 16-week ...

In October 2024, NTLA announced positive data from the ongoing phase I/II study of NTLA-2002 in HAE patients. These data, however, didn’t seem to impress investors and the stock was hit hard ...

NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for HAE, a rare genetic condition that results in recurrent attacks of severe swelling.

The researchers found that the estimated mean monthly attack rate was 0.70, 0.65, and 2.82 with 25mg NTLA-2002, 50mg NTLA-2002, and placebo, respectively (differences, −75 and −77% ...